Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907044 | 1.00 | DPP4 (0.49) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL990477 | 1.00 | DPP4 (0.49) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL5733961 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL7300435 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL10867215 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL5733967 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Serine SCHEMBL3839203 | 0.94 | DPP4 (0.45) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5735676 | 0.91 | GRB2 (0.46) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL3839201 | 0.86 | DPP4 (0.43) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL5207691 | 0.86 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186539-A2 | METHODS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2025-06-12 | — | — | US | claimed |
| EP-4464715-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTx Limited (GB) | 2024-11-20 | — | — | EP | claimed |
| US-20240325554-A1 | METHODS FOR TREATING CANCER | BICYCLE TX LTD (GB) | 2024-10-03 | — | — | US | claimed |
| CN-118028395-A | Method for synthesizing (S) -2-amino-3- (thiazole-4-yl) propionic acid by biological enzyme method | 中国科学院青岛生物能源与过程研究所 | 2024-05-14 | — | — | CN | claimed |
| EP-4274597-A1 | METHODS FOR TREATING CANCER | BicycleTX Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-116963757-A | Methods of treating cancer | 拜斯科技术开发有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2023-10-05 | — | — | US | claimed |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2023-04-27 | — | — | US | claimed |
| US-20220257784-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2022-08-18 | — | — | US | claimed |
| CN-114805487-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3810169-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTX Limited (GB) | 2021-04-28 | — | — | EP | claimed |
| CN-112601539-A | Bicyclic peptide ligands specific for bindin-4 | 拜斯科技术开发有限公司 | 2021-04-02 | — | — | CN | claimed |
| WO-2021019246-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| WO-2021019245-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | claimed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2019243832-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2019-12-26 | — | — | WO | claimed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | DPP4 968/4885DPP8 446/4885DPP9 335/4885 |
| US-20240325554-A1 | METHODS FOR TREATING CANCER | CD44, TUBB4A, TUBB3 | DPP4 2226/4885DPP8 4128/4885DPP9 3621/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | DPP4 616/4885DPP8 268/4885DPP9 283/4885 |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | CD44, TUBB4A, TUBB3 | DPP4 2226/4885DPP8 4128/4885DPP9 3621/4885 |
| US-20220257784-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | DPP4 1838/4885DPP8 1298/4885DPP9 2192/4885 |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TAP1, TIMCC, CD81 | DPP4 917/4885DPP8 498/4885DPP9 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.